Why carry out this study?

Plaque psoriasis (PSO) is an immune-mediated disease associated with increased mortality, substantial impact on quality of life and major economic burden to health systems

Over the past decade, several biologic therapies have been introduced for the treatment of moderate to severe psoriasis, which led to a transformational impact on treatment outcomes. Nevertheless, the evidence on the role of biologic treatments in the management of moderate to severe PSO is largely based on placebo-controlled randomised controlled trials with limited head-to-head comparisons

What did the study ask?/What was the hypothesis of the study?

This systematic literature review and network meta-analysis (NMA) evaluated the comparative efficacy of bimekizumab and other approved biologic therapies in achieving skin clearance (as examined using the Psoriasis Area and Severity Index) within 10 to 16 weeks of treatment

What were the study outcomes/conclusions? (data)

At 10 to 16 weeks, the NMA (k = 86) demonstrated that interleukin (IL)-17 and IL-23 inhibitors were more effective treatments than tumour necrosis factor inhibitors across all PASI response levels with bimekizumab 320 mg displaying the highest probability of achieving PASI 75, PASI 90 and PASI 100

What has been learned from the study?

Bimekizumab demonstrated statistical superiority over all biologics in achieving PASI 90 and PASI 100 thresholds, whereas for PASI 75, the benefit of bimekizumab was statistically significant compared to all other treatments except risankizumab and ixekizumab